세계의 톡소플라스마증 치료제 시장 : 유형별, 투여 경로별, 유통 채널별-기회 분석 및 산업 예측(2021-2031년)

The global toxoplasmosis treatment market was valued at $683.11 million in 2021, and is projected to reach $1,093.88 million by 2031, registering a CAGR of 4.8% from 2022 to 2031. Toxoplasmosis is a disease that occurs due to Toxoplasma gondii parasite, which is one of the world's most common parasites. This infection usually occurs by eating undercooked contaminated meat, exposure from infected cat feces, or mother-to-child transmission during pregnancy. Toxoplasmosis may cause flu-like symptoms in some people, however majority of those infected never show any signs or symptoms.

The growth of global toxoplasmosis treatment market is majorly driven by increase in prevalence of foodborne illness. In addition, technological advancement in treatment and diagnosis for toxoplasmosis disease propels the market growth. Furthermore, increase in awareness regarding toxoplasmosis treatment in developed countries such as the U.S. further fuels the market growth.

In addition, increase in prevalence of HIV across the globe has increased the risk of toxoplasma gondii infection due to less immune response in HIV infected patients that lead to rise in demand for toxoplasmosis treatment and propels the market growth. For instance, according to the World Health Organization (WHO), by the end of 2021, around 38.4 million people were living with HIV across the globe, therefore it is expected to increase the prevalence of toxoplasmosis infection among the global population that drives the market growth.

Furthermore, surge in healthcare, industrial development, and investments by the government and private organizations in Asia-Pacific, along with rise in awareness regarding toxoplasmosis disease is anticipated to positively impact the market during the forecast period. Moreover, product launch for toxoplasmosis treatment by the key market players are the boosting factors for the market growth. For instance, Dr. Reddy's Laboratories Ltd. announced the launch of pyrimethamine tablet USP, 25 mg, approved by the U.S. Food and Drug Administration (USFDA) for the treatment of toxoplasmosis.

However, side effects of toxoplasmosis drugs and high cost of treatment hinder the market growth. Conversely, rise in product approvals for toxoplasmosis treatment is anticipated to provide lucrative opportunities to the market players.

The toxoplasmosis treatment market is segmented on the basis of type, route of administration, distribution channel, and region. By type, the market is categorized into acquired toxoplasmosis and congenital toxoplasmosis. On the basis of route of administration, the market is segregated into oral and parenteral. By distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global toxoplasmosis treatment market are Alvogen, Dr. Reddy's Laboratories Ltd., Kaiser Permanente, Mangalam Drugs and Organics Ltd., Manus Aktteva Biopharma LLP, Oakrum Pharma, Omicron pharmaceuticals, Teva Pharmaceutical Industries Ltd., Vyera Pharmaceuticals LLC, and Zorish Healthcare Private Limited. 

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the toxoplasmosis treatment market analysis from 2021 to 2031 to identify the prevailing toxoplasmosis treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the toxoplasmosis treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global toxoplasmosis treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

• Acquired Toxoplasmosis
• Congenital Toxoplasmosis

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Providers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Arabia
  • Rest of LAMEA
• Key Market Players
  • Alvogen
  • Dr Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Limited
  • Vyera Pharmaceuticals LLC
  • Mangalam Drugs and Organics Ltd.
  • Oakrum Pharma
  • Kaiser Permanente
  • Zorish Healthcare Private Limited
  • omicron pharmaceuticals
  • Manus Aktteva Biopharma LLP

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: TOXOPLASMOSIS TREATMENT MARKET, BY TYPE

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Acquired Toxoplasmosis
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market share analysis by country
• 4.3 Congenital Toxoplasmosis
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market share analysis by country

CHAPTER 5: TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Oral
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market share analysis by country
• 5.3 Parenteral
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market share analysis by country

CHAPTER 6: TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Hospital Pharmacies
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market share analysis by country
• 6.3 Drug Stores and Retail Pharmacies
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market share analysis by country
• 6.4 Online Providers
  • 6.4.1 Key market trends, growth factors and opportunities
  • 6.4.2 Market size and forecast, by region
  • 6.4.3 Market share analysis by country

CHAPTER 7: TOXOPLASMOSIS TREATMENT MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Type
  • 7.2.3 North America Market size and forecast, by Route of Administration
  • 7.2.4 North America Market size and forecast, by Distribution Channel
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Key market trends, growth factors and opportunities
    • 7.2.5.1.2 Market size and forecast, by Type
    • 7.2.5.1.3 Market size and forecast, by Route of Administration
    • 7.2.5.1.4 Market size and forecast, by Distribution Channel
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Key market trends, growth factors and opportunities
    • 7.2.5.2.2 Market size and forecast, by Type
    • 7.2.5.2.3 Market size and forecast, by Route of Administration
    • 7.2.5.2.4 Market size and forecast, by Distribution Channel
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Key market trends, growth factors and opportunities
    • 7.2.5.3.2 Market size and forecast, by Type
    • 7.2.5.3.3 Market size and forecast, by Route of Administration
    • 7.2.5.3.4 Market size and forecast, by Distribution Channel
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Type
  • 7.3.3 Europe Market size and forecast, by Route of Administration
  • 7.3.4 Europe Market size and forecast, by Distribution Channel
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Key market trends, growth factors and opportunities
    • 7.3.5.1.2 Market size and forecast, by Type
    • 7.3.5.1.3 Market size and forecast, by Route of Administration
    • 7.3.5.1.4 Market size and forecast, by Distribution Channel
    • 7.3.5.2 France
    • 7.3.5.2.1 Key market trends, growth factors and opportunities
    • 7.3.5.2.2 Market size and forecast, by Type
    • 7.3.5.2.3 Market size and forecast, by Route of Administration
    • 7.3.5.2.4 Market size and forecast, by Distribution Channel
    • 7.3.5.3 UK
    • 7.3.5.3.1 Key market trends, growth factors and opportunities
    • 7.3.5.3.2 Market size and forecast, by Type
    • 7.3.5.3.3 Market size and forecast, by Route of Administration
    • 7.3.5.3.4 Market size and forecast, by Distribution Channel
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Key market trends, growth factors and opportunities
    • 7.3.5.4.2 Market size and forecast, by Type
    • 7.3.5.4.3 Market size and forecast, by Route of Administration
    • 7.3.5.4.4 Market size and forecast, by Distribution Channel
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Key market trends, growth factors and opportunities
    • 7.3.5.5.2 Market size and forecast, by Type
    • 7.3.5.5.3 Market size and forecast, by Route of Administration
    • 7.3.5.5.4 Market size and forecast, by Distribution Channel
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Key market trends, growth factors and opportunities
    • 7.3.5.6.2 Market size and forecast, by Type
    • 7.3.5.6.3 Market size and forecast, by Route of Administration
    • 7.3.5.6.4 Market size and forecast, by Distribution Channel
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Type
  • 7.4.3 Asia-Pacific Market size and forecast, by Route of Administration
  • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Key market trends, growth factors and opportunities
    • 7.4.5.1.2 Market size and forecast, by Type
    • 7.4.5.1.3 Market size and forecast, by Route of Administration
    • 7.4.5.1.4 Market size and forecast, by Distribution Channel
    • 7.4.5.2 China
    • 7.4.5.2.1 Key market trends, growth factors and opportunities
    • 7.4.5.2.2 Market size and forecast, by Type
    • 7.4.5.2.3 Market size and forecast, by Route of Administration
    • 7.4.5.2.4 Market size and forecast, by Distribution Channel
    • 7.4.5.3 India
    • 7.4.5.3.1 Key market trends, growth factors and opportunities
    • 7.4.5.3.2 Market size and forecast, by Type
    • 7.4.5.3.3 Market size and forecast, by Route of Administration
    • 7.4.5.3.4 Market size and forecast, by Distribution Channel
    • 7.4.5.4 Australia
    • 7.4.5.4.1 Key market trends, growth factors and opportunities
    • 7.4.5.4.2 Market size and forecast, by Type
    • 7.4.5.4.3 Market size and forecast, by Route of Administration
    • 7.4.5.4.4 Market size and forecast, by Distribution Channel
    • 7.4.5.5 South Korea
    • 7.4.5.5.1 Key market trends, growth factors and opportunities
    • 7.4.5.5.2 Market size and forecast, by Type
    • 7.4.5.5.3 Market size and forecast, by Route of Administration
    • 7.4.5.5.4 Market size and forecast, by Distribution Channel
    • 7.4.5.6 Rest of Asia-Pacific
    • 7.4.5.6.1 Key market trends, growth factors and opportunities
    • 7.4.5.6.2 Market size and forecast, by Type
    • 7.4.5.6.3 Market size and forecast, by Route of Administration
    • 7.4.5.6.4 Market size and forecast, by Distribution Channel
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Type
  • 7.5.3 LAMEA Market size and forecast, by Route of Administration
  • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Key market trends, growth factors and opportunities
    • 7.5.5.1.2 Market size and forecast, by Type
    • 7.5.5.1.3 Market size and forecast, by Route of Administration
    • 7.5.5.1.4 Market size and forecast, by Distribution Channel
    • 7.5.5.2 Saudi Arabia
    • 7.5.5.2.1 Key market trends, growth factors and opportunities
    • 7.5.5.2.2 Market size and forecast, by Type
    • 7.5.5.2.3 Market size and forecast, by Route of Administration
    • 7.5.5.2.4 Market size and forecast, by Distribution Channel
    • 7.5.5.3 South Arabia
    • 7.5.5.3.1 Key market trends, growth factors and opportunities
    • 7.5.5.3.2 Market size and forecast, by Type
    • 7.5.5.3.3 Market size and forecast, by Route of Administration
    • 7.5.5.3.4 Market size and forecast, by Distribution Channel
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Key market trends, growth factors and opportunities
    • 7.5.5.4.2 Market size and forecast, by Type
    • 7.5.5.4.3 Market size and forecast, by Route of Administration
    • 7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 Alvogen
  • 9.1.1 Company overview
  • 9.1.2 Company snapshot
  • 9.1.3 Operating business segments
  • 9.1.4 Product portfolio
  • 9.1.5 Business performance
  • 9.1.6 Key strategic moves and developments
• 9.2 Dr Reddy's Laboratories Ltd.
  • 9.2.1 Company overview
  • 9.2.2 Company snapshot
  • 9.2.3 Operating business segments
  • 9.2.4 Product portfolio
  • 9.2.5 Business performance
  • 9.2.6 Key strategic moves and developments
• 9.3 Teva Pharmaceutical Industries Limited
  • 9.3.1 Company overview
  • 9.3.2 Company snapshot
  • 9.3.3 Operating business segments
  • 9.3.4 Product portfolio
  • 9.3.5 Business performance
  • 9.3.6 Key strategic moves and developments
• 9.4 Vyera Pharmaceuticals LLC
  • 9.4.1 Company overview
  • 9.4.2 Company snapshot
  • 9.4.3 Operating business segments
  • 9.4.4 Product portfolio
  • 9.4.5 Business performance
  • 9.4.6 Key strategic moves and developments
• 9.5 Mangalam Drugs and Organics Ltd.
  • 9.5.1 Company overview
  • 9.5.2 Company snapshot
  • 9.5.3 Operating business segments
  • 9.5.4 Product portfolio
  • 9.5.5 Business performance
  • 9.5.6 Key strategic moves and developments
• 9.6 Oakrum Pharma
  • 9.6.1 Company overview
  • 9.6.2 Company snapshot
  • 9.6.3 Operating business segments
  • 9.6.4 Product portfolio
  • 9.6.5 Business performance
  • 9.6.6 Key strategic moves and developments
• 9.7 Kaiser Permanente
  • 9.7.1 Company overview
  • 9.7.2 Company snapshot
  • 9.7.3 Operating business segments
  • 9.7.4 Product portfolio
  • 9.7.5 Business performance
  • 9.7.6 Key strategic moves and developments
• 9.8 Zorish Healthcare Private Limited
  • 9.8.1 Company overview
  • 9.8.2 Company snapshot
  • 9.8.3 Operating business segments
  • 9.8.4 Product portfolio
  • 9.8.5 Business performance
  • 9.8.6 Key strategic moves and developments
• 9.9 omicron pharmaceuticals
  • 9.9.1 Company overview
  • 9.9.2 Company snapshot
  • 9.9.3 Operating business segments
  • 9.9.4 Product portfolio
  • 9.9.5 Business performance
  • 9.9.6 Key strategic moves and developments
• 9.10 Manus Aktteva Biopharma LLP
  • 9.10.1 Company overview
  • 9.10.2 Company snapshot
  • 9.10.3 Operating business segments
  • 9.10.4 Product portfolio
  • 9.10.5 Business performance
  • 9.10.6 Key strategic moves and developments